Detalhe da pesquisa
1.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363833
2.
Fatal Hemophagocytic Lymphohistiocytosis in a Patient with Miliary Tuberculosis: a Case Report.
SN Compr Clin Med
; 4(1): 152, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35856014
3.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Lancet Haematol
; 9(3): e190-e199, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35240075